SCHEMBL4155681

SCHEMBL4155681

COC(=O)C1NCC(NOCc2ccccc2)c2c[nH]nc21

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.34
TSHR P16473 3/20 0.34
CYP3A4 P08684 2/20 0.34
CASP1 P29466 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
CPB1 P15086 1/20 0.34
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33
HTR2C P28335 1/20 0.33
CYP2D6 P10635 1/20 0.33
EPHX2 P34913 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4147766 0.99 TSHR (0.34) ALDH1A1TSHRCYP3A4CASP1SMN1; SMN2
SCHEMBL4694770 0.90 NPC1 (0.35) ALDH1A1NPC1RAB9AHTR2CEPHX2
SCHEMBL5187221 0.85 NPC1 (0.37) ALDH1A1TSHRCYP3A4CASP1SMN1; SMN2
SCHEMBL20557971 0.83 CCNB2 (0.35) ALDH1A1TSHRCYP3A4CASP1SMN1; SMN2
SCHEMBL4136748 0.80 TSHR (0.34) ALDH1A1TSHRCYP3A4CASP1SMN1; SMN2
SCHEMBL20558125 0.79 ACHE (0.34) ALDH1A1NPC1RAB9ACPB1HTR2C
Hydrochloric Acid SCHEMBL4145877 0.77 HTT (0.39) ALDH1A1NPC1HPGD
SCHEMBL5330841 0.77 TSHR (0.40) ALDH1A1TSHRNPC1RAB9AHTR2C
SCHEMBL22030527 0.74 PARP1 (0.40) ALDH1A1POLBMAPTNPSR1
SCHEMBL20558166 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018329-A1 NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTIBACTERIALS AND BETA-LACTAMASE INHIBITORS NOVEXEL (FR) 2009-01-15 US disclosed
US-7439253-B2 Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors NOVEXEL (FR) 2008-10-21 US disclosed
US-20040157826-A1 Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors AVENTIS PHARMA S.A. (FR) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157826-A1 Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors GAA, ALPI, GANAB ALDH1A1 305/4885TSHR 4594/4885CYP3A4 559/4885
US-20090018329-A1 NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTIBACTERIALS AND BETA-LACTAMASE INHIBITORS GAA, GANAB, ALPI ALDH1A1 433/4885TSHR 4591/4885CYP3A4 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.